Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia

• Published in: Zhongguo shi yan xue ye xue za zhi Vol. 24; no. 1; p. 72
• Main Authors: Guo, Jia, Zhu, Yi-Ping, Gao, Ju, Li, Qiang, Jia, Cang-Song, Zhou, Chen-Yan, Guo, Xia
• Format: Journal Article
• Language: Chinese
• Published: China 01.02.2016
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Burkitt Lymphoma - diagnosis; Burkitt Lymphoma - drug therapy; Child; Cyclophosphamide - therapeutic use; Cytarabine - therapeutic use; Disease-Free Survival; Doxorubicin - therapeutic use; Etoposide - therapeutic use; Female; Humans; Hydrocortisone - therapeutic use; Leucovorin - therapeutic use; Logistic Models; Lymphoma, B-Cell - diagnosis; Lymphoma, B-Cell - drug therapy; Lymphoma, Large B-Cell, Diffuse - diagnosis; Lymphoma, Large B-Cell, Diffuse - drug therapy; Male; Methotrexate - therapeutic use; Multivariate Analysis; Neoplasm Staging; Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Prednisone - therapeutic use; Prognosis; Retrospective Studies; Survival Rate; Vincristine - therapeutic use
• ISSN: 1009-2137
• DOI: 10.7534/j.issn.1009-2137.2016.01.014

To explore the clinical and prognostic features as well as treatment response of childhood B-cell non-Hodgkin's lymphoma/acute lymphoblastic leukemia (B-NHL/B-ALL), so as to better modify the treatment for further improving the prognosis. The clinical data of 43 patients with newly-diagnosed childhood B-NHL/B-ALL from July 2005 to December 2013 in West China Second Hospital of Sichuan University were retrospectively analyzed with particular focus on clinical presentations, laboratory findings and histology. Among them 26 patients received B-NHL-2010 protocol and 17 patients received LMB-89 protocol treatment. Kaplan-Meier method was used to compare the survival rates between groups, while multiple factor logistic regression was used to identify the prognostic factors. (1) The median age at diagnosis was 7.58 (2.42-13.67) years. The male-to-female ratio was 2.9 : 1. No significant difference was found in the median age at diagnosis between male and female children with B-NHL/B-ALL (P = 0.837). (2) Burkitt's ly